EGFR and neoplasm: In addition to mutations that reduce affinity for EGFR inhibitors, tumor cells can develop resistance through mechanisms (Table 2) such as histologic transformation or activating other receptor tyrosine kinases (RTKs) and alternative downstream pathways (Figure 1).